Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
OMNIFARMA LLC
Age
45–55
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
availability of a signed Informed Consent (Information Sheet) of the patient to participate in the clinical trial;
female patients in the postmenopausal period (1-4 years) with hypertension (stage I-II, stage I-II), which is established according to the classification of arterial hypertension (HTN) by stages, degrees and cardiovascular risk.
Accordingly, the indicators SBP within 140 - 159 mmHg, DBP 90 - 99 mmHg - HTN stage I;
SBP within 160 - 179 mmHg, DBP 100 - 109 mmHg - HTN stage II. Depending on the damage to target organs:
Stage I - objective signs of organic damage to target organs are absent; Stage II - there are objective signs of target organ damage without symptoms or dysfunction: LV hypertrophy (according to ECG, Echo-CG, MRI).
reduced bone mineral density (BMD), which meets the criteria for osteopenia of the I-III degree, established by ultrasound densitometry: osteopenia of the I degree T-score from -1.0 to -1.5, II degree T-score from -1.5 to -2.0, III degree T-score from -2.0 to -2.5;
patient's readiness for adequate cooperation in the process of clinical trials.
You may not be if
diagnosed congenital or acquired heart defects;
established non-coronary myocardial diseases (myocarditis, cardiomyopathy);
rhythm or conduction disorders with concomitant hemodynamic disorders (extrasystoles, paroxysmal tachycardias, atrial fibrillation/flutter, AV block 2 and 3 degrees);
endocrine diseases, blood system diseases, systemic connective tissue diseases;
diagnosed chronic obstructive pulmonary disease;
impaired renal function (glomerular filtration rate according to the CKD-EPI formula less than 60 ml/min), liver.
